Bristol Pravigard PAC Set For August Launch At Pravachol AWP
Executive Summary
Bristol-Myers Squibb will launch its pravastatin/aspirin combination Pravigard PAC in August at the same average wholesale price as the cholesterol-lowering agent Pravachol (pravastatin)
You may also be interested in...
Bristol Pravachol/Aspirin Co-Package Not Precedent For Combo Submissions
Bristol-Myers Squibb's Pravachol/aspirin combination should not be viewed as a precedent for approval of other combination products, FDA's Cardiovascular & Renal Drugs Advisory Committee members suggested July 18
Pravachol/Aspirin Fixed-Dose Inflexibility May Lead To Undertreatment
Bristol-Myers Squibb's Pravachol/Bufferin titration inflexibility was cited as a main issue by FDA's Cardiovascular & Renal Drugs Advisory Committee in voting against approval of the fixed-dose combination of the cholesterol-lowering and aspirin products
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011